Climate Change Data

Environmental Metrics

ESG Focus Areas

• Not disclosed

Environmental Achievements

• Not disclosed

Social Achievements

• Expanded production space with a new cleanroom specifically for microfluidic device manufacturing. The company is now competent in producing devices with feature size down to 50µm.

Governance Achievements

• Not disclosed

Climate Goals & Targets

Environmental Challenges

• To increase its market share, InziGn is seeking to expand its core business into microfluidic devices manufacturing.

Mitigation Strategies

• Acquired SIMTech’s technology in microfluidic devices manufacturing, supported by SMF and ETPL. Successfully completed technology transfer in December 2014.

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement

• Not disclosed

Climate-Related Risks & Opportunities

Physical Risks

• Not disclosed

Transition Risks

• Not disclosed

Opportunities

• Not disclosed

Reporting Standards

Frameworks Used: Null

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

• Not disclosed

Not disclosed

Sustainable Products & Innovation

• Not disclosed

Awards & Recognition

• Not disclosed

Environmental Metrics

Climate Goals & Targets

Environmental Challenges

• Our business is significantly dependent on several of our major customers’ business performance and our relationship with them, and we may be unable to attract or be successful in attracting new customers
• We may be unable to price our molded plastic parts at our desired margins as a result of any decrease in our bargaining power or changes in market conditions
• If our production facility, production processes or molded plastic parts fail to meet the required quality standards, it could harm our business and reputation, and our turnovers and profitability could be materially and adversely affected
• We are subject to risks relating to the operation of our production facilities
• A significant portion of our workforce is made up of foreign labour and any difficulties in recruiting and/or retaining foreign labour could materially and adversely affect our operations and financial performance
• We are involved in a litigation with one of our past suppliers and we cannot assure you that such legal proceedings will not have a material adverse impact on our image and business
• Our customers may amend their demand forecasts, change production quantities or delay production, which may in turn affect our results of operations
• The successful implementation of production processes of our customer is subject to significant business, economic and competitive uncertainties
• We may experience failure in the future for the production of new parts manufactured for our existing or new customers
• We may be unable to meet specifications of our customers
• We are subject to risks associated with the overseas sales of our molded plastic parts for disposable medical devices
• Inability to attract and/or retain management staff could materially and adversely affect our operations and financial performance
• Any disruption to the supply or quality or safety problems of our raw materials or packaging materials could materially and adversely affect our production, turnover and profitability
• Our ability to control the prices of our key raw materials may significantly impact our results of operations
• Our net current liabilities position may expose us to certain liquidity risks and could constrain our operational flexibility as well as materially and adversely affect our ability to expand our business
• Our Group’s financial results may be affected in the future arising from our Group’s financial instruments which are carried at fair value
• Our level of indebtedness may adversely affect our business and liquidity position
• Our exposure to credit risk may adversely affect our business operations and financial position
• We may be unable to efficiently manage our inventory risks
• Our net cash outflow from operating activities may affect our liquidity
• Taxation authorities could challenge our allocation of taxable income which could increase our consolidated tax liability
• Our operation may be subject to production malfunction, failure in information technology system, as well as to disruptions caused by injury to workers from the use of production equipment
• Our production facility in Batam, Indonesia, is subject to significant risks of earthquakes, volcanic eruption and other natural disasters
• Our expansion plan may not be as successful as we have planned
• Our Group’s implementation of our business strategies may result in disproportionate increase in staff costs if there is any failure or delay in implementing any part of the business strategies, in particular if the forecasted volumes of our customers under the three new processes are significantly decreased
• We may be unable to secure additional funds in the future to fund our operations or expansion plans
• We may not be eligible to or be able to continue to secure the existing government grants which we enjoy
• We may be unable to successfully implement our strategies, or achieve our business objectives and our business, operating results and financial position may be materially and adversely affected
• The industry which we are in is interrelated to the medical device industry where our customers are based in, the latter of which is highly regulated in Singapore and other countries where our customers are located. Any change in the applicable laws, regulations or standards governing the business of our customers may prevent or restrict us from manufacturing certain parts or subject us to increased costs of compliance
• If the Singapore government or government of countries where our customers are located decide to impose price control on them, our business, profitability, results of operations and prospects would be materially and adversely affected
• There has been stricter government policies on foreign manpower since 2013
• There is no guarantee that regulatory requirements applicable to the industry in which we operate will not change in the future
• The interpretation and implementation of legislation on regional governance in Indonesia is uncertain
• Termination of the Public Offer Underwriting Agreement
• The liquidity, market price and trading volume of our Shares may be volatile
• Investors for our Shares may experience dilution if we issue additional Shares in the future to raise funding
• There may be dilution because of the issuance of Shares pursuant to the options which may be granted under the Share Option Scheme
• We cannot guarantee the accuracy of facts and other statistics with respect to certain information relating to the economics and the industry in which we operate contained in this prospectus
• Forward-looking statements contained in this prospectus are subject to risks and uncertainties
• We strongly caution you not to place any reliance on any information (if any) contained in press articles or other media regarding us or the Share Offer

Mitigation Strategies

• We will continue to endeavor to diversify and expand our customer base
• We periodically review our costs of production and negotiate with the customer on prices for our molded plastic parts
• We have established quality control management system and standard operating procedures to help prevent quality issues in respect of our products
• We have established quality control management system and standard operating procedures to help prevent quality issues in respect of our products
• We will continue to endeavor to diversify and expand our customer base
• We anticipate we will need to divert management resources and incur extra time and costs to handle such Case
• We generally procure raw materials based on purchase orders, we may consult these forecasts as a basis for our procurement of certain raw materials that require a longer lead time to procure
• The successful implementation of the production processes of our customers is subject to significant business, economic and competitive uncertainties, including product development risks, the availability of funds, competition and regulation, and may be re-evaluated from time to time based on current regulations, government policies and the continuing growth of the medical device market
• We are dedicated to diversify our injection molding business
• We cannot assure you that we will be able to respond to changes in specifications of our customers resulted from emerging trends in a timely manner
• We are subject to a variety of risks and uncertainties associated with overseas operations and sales
• We also rely on our experienced senior management team to ensure the smooth operation of our projects, including adhering to quality and safety standards
• If any supplier is unwilling or unable to provide us with high quality raw materials in required quantities or specifications and at acceptable prices, we may be unable to find alternative sources at commercially acceptable prices, on satisfactory terms, in a timely manner, or at all
• We may be required to incur additional expenses in employing more local labour force in Singapore
• We cannot assure you that we will not experience any period of net cash outflow from operating activities in the future
• We have determined transfer prices that we believe are the same as the prices that would be charged by unrelated third parties dealing with each other on an arms’ length basis
• We have implemented an effective maintenance system for our production machineries
• We have implemented an inventory management policy, where we are required to regularly review our inventory level through our information technology system and by carrying out physical stock counts and internal audit
• We will continue to market our Group’s services and capabilities through targeted promotional activities with the aim to promote our services and capabilities to medical professionals and medical product owners
• We will continue to participate in major international medical specialty trade fairs, such as the MEDICA in Europe, the Medical Design & Manufacturing in the U.S. and the China International Medical Equipment Fair in China
• We also intend to cooperate with local government entities and hospitals and research institutions which can provide clinical trial support, academic studies and research in relation to their respective new products’ development; these will in turn help to introduce our capabilities and services to more product owners with whom the hospitals and these institutes’ medical professionals are collaborating
• We will continue to endeavor to diversify and expand our customer base
• We will continue to endeavor to diversify and expand our customer base
• We will continue to endeavor to diversify and expand our customer base

Supply Chain Management

Climate-Related Risks & Opportunities

Awards & Recognition

• Valued Business Partner award from JMS
• Supplier of the Year award from Customer A
• Long Service Award from Customer A

Environmental Metrics

ESG Focus Areas

• Environment
• Social
• Governance

Environmental Achievements

• Implemented measures to mitigate exhaust gas, VOCs, dust and PM emissions.
• Adopted measures to reduce GHG emissions from diesel consumption and electricity use.
• Implemented pollution prevention measures for industrial wastewater.
• Improved waste management practices, including segregation and disposal of hazardous and non-hazardous waste.
• Initiatives to improve energy and water efficiency.

Social Achievements

• Established a comprehensive employment management system providing a fair and inclusive working environment.
• Implemented safety management policies and regular safety training.
• Provided comprehensive health care coverage and work-life balancing activities for employees.
• Offered various training programs to enhance employee skills and knowledge.
• Implemented policies to prevent child and forced labor.
• Conducted annual supplier audits to evaluate social responsibility performance.
• Established a whistleblowing policy to address improprieties and misconduct.
• Participated in community activities, including donations and volunteering.

Governance Achievements

• Established an ESG working taskforce reporting to the Board of Directors.
• Implemented a formal Code of Conduct to address conflict of interests and other ethical concerns.
• Established an Internal Audit function to evaluate internal control effectiveness.

Climate Goals & Targets

Environmental Challenges

• Minimizing environmental impact of operations (emissions, waste, resource consumption).
• Maintaining a safe and healthy working environment.
• Ensuring ethical and responsible supply chain management.
• Preventing corruption and fraud.

Mitigation Strategies

• Formulated environmental management policies and implemented an EHS management system.
• Regular risk assessments and safety training programs.
• Annual supplier audits and remedial actions for violations.
• Formal Code of Conduct, internal audit function, and whistleblowing policy.

Supply Chain Management

Supplier Audits: Annual audits for major suppliers

Responsible Procurement

• Supplier selection based on social responsibility performance.

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: ESG Reporting Guide (Appendix 20 of the Rules Governing the Listing of Securities on Growth Enterprise Market of the Stock Exchange of Hong Kong Limited)

Certifications: ISO 9001, ISO 13485